The CANTOS trial highlighted the importance of direct anti-inflammatory therapies targeting the NLRP3 inflammasome-derived inflammatory cytokine IL-1β in secondary cardiovascular disease prevention [149]. This evidence concerns the gene NLRP3 and cardiovascular disorder.